Structural Considerations for Novel Small Molecule Agonists at the CXCR4 Chemokine Receptor
Session Number
P08
Advisor(s)
Brittany Hopkins, Northwestern University Richard Miller, Northwestern University
Location
A-121
Start Date
28-4-2016 10:40 AM
End Date
28-4-2016 11:05 AM
Abstract
In a prior study by Mishra et. al, numerous novel drugs were identified as possible ligands of the CXCR4 receptor, which plays many roles in diseases such as human immunodeficiency virus (HIV), Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) syndrome, and at least 23 types of cancer. This study takes a more detailed look into one of the prospective agonists found in the screening of the study, drug 54118. When the CXCR4 receptor is activated, downstream signaling leads to increased levels of intracellular calcium ions. A calcium-imaging assay was used, in which human melanoma cells are incubated in fura-2 dye and injected with various concentrations of drug 54118 to see changes calcium levels. From calcium imaging, a dose-response curve was created from the data depicting the efficacy of the drug at different concentrations. Based on the results, 54118 was confirmed to be a robust agonist of the CXCR4 receptor, and the EC50 value was found to be 0.1497. By looking at possible agonists and antagonists for the CXCR4 receptor, new understandings and advancements in treatments for cancer, HIV-1 and WHIM can arise.
Structural Considerations for Novel Small Molecule Agonists at the CXCR4 Chemokine Receptor
A-121
In a prior study by Mishra et. al, numerous novel drugs were identified as possible ligands of the CXCR4 receptor, which plays many roles in diseases such as human immunodeficiency virus (HIV), Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) syndrome, and at least 23 types of cancer. This study takes a more detailed look into one of the prospective agonists found in the screening of the study, drug 54118. When the CXCR4 receptor is activated, downstream signaling leads to increased levels of intracellular calcium ions. A calcium-imaging assay was used, in which human melanoma cells are incubated in fura-2 dye and injected with various concentrations of drug 54118 to see changes calcium levels. From calcium imaging, a dose-response curve was created from the data depicting the efficacy of the drug at different concentrations. Based on the results, 54118 was confirmed to be a robust agonist of the CXCR4 receptor, and the EC50 value was found to be 0.1497. By looking at possible agonists and antagonists for the CXCR4 receptor, new understandings and advancements in treatments for cancer, HIV-1 and WHIM can arise.